The estimated Net Worth of Adam Hansard is at least 4.17 百万$ dollars as of 14 March 2024. Mr Hansard owns over 48,871 units of Applied Therapeutics stock worth over 3,818,508$ and over the last 5 years he sold APLT stock worth over 348,755$.
Mr has made over 5 trades of the Applied Therapeutics stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 48,871 units of APLT stock worth 263,415$ on 14 March 2024.
The largest trade he's ever made was selling 48,871 units of Applied Therapeutics stock on 14 March 2024 worth over 263,415$. On average, Mr trades about 5,579 units every 85 days since 2020. As of 14 March 2024 he still owns at least 732,919 units of Applied Therapeutics stock.
You can see the complete history of Mr Hansard stock trades at the bottom of the page.
Adam Hansard is the Chief Commercial Officer at Applied Therapeutics.
Mr Hansard is 45, he's been the Chief Commercial Officer of Applied Therapeutics since . There are 9 older and 2 younger executives at Applied Therapeutics. The oldest executive at Applied Therapeutics, Inc. is Jay Skyler, 73, who is the Independent Director.
Adam's mailing address filed with the SEC is C/O APPLIED THERAPEUTICS, INC., 545 FIFTH AVENUE, SUITE 1400, NEW YORK, NY, 10017.
Over the last 6 years, insiders at Applied Therapeutics have traded over 14,309,660$ worth of Applied Therapeutics stock and bought 5,072,897 units worth 17,896,654$ . The most active insiders traders include Real Estate Equities, Inc.A...、Joel S Marcus、Shoshana Shendelman. On average, Applied Therapeutics executives and independent directors trade stock every 26 days with the average trade being worth of 573,736$. The most recent stock trade was executed by Leslie D. Funtleyder on 22 August 2024, trading 13,530 units of APLT stock currently worth 78,880$.
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase I/II for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy. Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.
Applied Therapeutics executives and other stock owners filed with the SEC include: